匹斯克利丁缓解膝骨关节炎患者症状的疗效及其对血脂水平和体重指数的影响

Hoang Minh Phan, Cang Trung Huynh, Phu Van La, Khanh Hoang Pham, Phuong Minh Vo, Trang Huynh Vo
{"title":"匹斯克利丁缓解膝骨关节炎患者症状的疗效及其对血脂水平和体重指数的影响","authors":"Hoang Minh Phan, Cang Trung Huynh, Phu Van La, Khanh Hoang Pham, Phuong Minh Vo, Trang Huynh Vo","doi":"10.5455/medarh.2024.78.296-301","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Piascledine is a potential treatment for osteoarthritis; however, current evidence regarding its efficacy in patients with knee osteoarthritis remains limited.</p><p><strong>Objective: </strong>To evaluate the efficacy of Piascledine in improving symptoms and its impact on blood lipid levels and body mass index in patients with knee osteoarthritis.</p><p><strong>Methods: </strong>A randomized, controlled, single-blind clinical trial. The odd-numbered group was treated with Piascledine at a dose of 300mg/day, while the even-numbered group was treated with glucosamine sulfate at a dose of 1,500mg/day. Outcomes were assessed at 4 weeks and 8 weeks.</p><p><strong>Results: </strong>A total of 200 patients were included in the study, with a mean age of 58.5 ± 11.3 years, of whom 42.0% were male. Obesity (OR=2.83; 95% CI: 1.88-4.26; p<0.001) and hypertriglyceridemia (OR=2.07; 95% CI: 1.17-3.67; p<0.05) were identified as factors significantly increasing the risk of severe osteoarthritis. At 4 weeks and 8 weeks, the Piascledine group showed a reduction in VAS scores from 49.3 ± 19.6mm to 37.6 ± 14.2mm and 25.3 ± 10.2mm, respectively. At 4 weeks, the VAS and WOMAC scores showed greater improvement in the GCS group compared to the Piascledine group. However, at 8 weeks, there was no significant difference in efficacy between the two groups. Treatment with Piascledine slightly increased triglyceride levels from 2.3 ± 1.4mmol/L to 2.7 ± 1.4mmol/L. Side effects were observed in 16.0% of patients during treatment, with the most common being nausea (10.0%).</p><p><strong>Conclusion: </strong>The study indicates that obesity and hypertriglyceridemia are risk factors for severe knee osteoarthritis. Treatment with Piascledine improves symptoms and knee joint function, without impacting body mass index or lipid metabolism. The majority of side effects were mild and primarily gastrointestinal.</p>","PeriodicalId":94135,"journal":{"name":"Medical archives (Sarajevo, Bosnia and Herzegovina)","volume":"78 4","pages":"296-301"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11838829/pdf/","citationCount":"0","resultStr":"{\"title\":\"The Efficacy of Piascledine in Alleviating Symptoms and Its Impact on Blood Lipid Levels and body Mass Index in Patients with Knee Osteoarthritis.\",\"authors\":\"Hoang Minh Phan, Cang Trung Huynh, Phu Van La, Khanh Hoang Pham, Phuong Minh Vo, Trang Huynh Vo\",\"doi\":\"10.5455/medarh.2024.78.296-301\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Piascledine is a potential treatment for osteoarthritis; however, current evidence regarding its efficacy in patients with knee osteoarthritis remains limited.</p><p><strong>Objective: </strong>To evaluate the efficacy of Piascledine in improving symptoms and its impact on blood lipid levels and body mass index in patients with knee osteoarthritis.</p><p><strong>Methods: </strong>A randomized, controlled, single-blind clinical trial. The odd-numbered group was treated with Piascledine at a dose of 300mg/day, while the even-numbered group was treated with glucosamine sulfate at a dose of 1,500mg/day. Outcomes were assessed at 4 weeks and 8 weeks.</p><p><strong>Results: </strong>A total of 200 patients were included in the study, with a mean age of 58.5 ± 11.3 years, of whom 42.0% were male. Obesity (OR=2.83; 95% CI: 1.88-4.26; p<0.001) and hypertriglyceridemia (OR=2.07; 95% CI: 1.17-3.67; p<0.05) were identified as factors significantly increasing the risk of severe osteoarthritis. At 4 weeks and 8 weeks, the Piascledine group showed a reduction in VAS scores from 49.3 ± 19.6mm to 37.6 ± 14.2mm and 25.3 ± 10.2mm, respectively. At 4 weeks, the VAS and WOMAC scores showed greater improvement in the GCS group compared to the Piascledine group. However, at 8 weeks, there was no significant difference in efficacy between the two groups. Treatment with Piascledine slightly increased triglyceride levels from 2.3 ± 1.4mmol/L to 2.7 ± 1.4mmol/L. Side effects were observed in 16.0% of patients during treatment, with the most common being nausea (10.0%).</p><p><strong>Conclusion: </strong>The study indicates that obesity and hypertriglyceridemia are risk factors for severe knee osteoarthritis. Treatment with Piascledine improves symptoms and knee joint function, without impacting body mass index or lipid metabolism. The majority of side effects were mild and primarily gastrointestinal.</p>\",\"PeriodicalId\":94135,\"journal\":{\"name\":\"Medical archives (Sarajevo, Bosnia and Herzegovina)\",\"volume\":\"78 4\",\"pages\":\"296-301\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11838829/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medical archives (Sarajevo, Bosnia and Herzegovina)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5455/medarh.2024.78.296-301\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical archives (Sarajevo, Bosnia and Herzegovina)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5455/medarh.2024.78.296-301","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景:匹斯克莱丁是治疗骨关节炎的潜在药物;然而,目前关于其在膝关节骨关节炎患者中的疗效的证据仍然有限。目的:评价匹亚斯克利丁对膝骨性关节炎患者症状的改善效果及其对血脂水平和体重指数的影响。方法:随机、对照、单盲临床试验。奇数组给予吡哌替啶300mg/d,偶数组给予硫酸氨基葡萄糖1500mg /d。在4周和8周时评估结果。结果:共纳入200例患者,平均年龄58.5±11.3岁,其中男性42.0%。肥胖(OR = 2.83;95% ci: 1.88-4.26;结论:肥胖和高甘油三酯血症是严重膝骨关节炎的危险因素。吡氯定治疗可改善症状和膝关节功能,不影响体重指数或脂质代谢。大多数副作用是轻微的,主要是胃肠道的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
The Efficacy of Piascledine in Alleviating Symptoms and Its Impact on Blood Lipid Levels and body Mass Index in Patients with Knee Osteoarthritis.

Background: Piascledine is a potential treatment for osteoarthritis; however, current evidence regarding its efficacy in patients with knee osteoarthritis remains limited.

Objective: To evaluate the efficacy of Piascledine in improving symptoms and its impact on blood lipid levels and body mass index in patients with knee osteoarthritis.

Methods: A randomized, controlled, single-blind clinical trial. The odd-numbered group was treated with Piascledine at a dose of 300mg/day, while the even-numbered group was treated with glucosamine sulfate at a dose of 1,500mg/day. Outcomes were assessed at 4 weeks and 8 weeks.

Results: A total of 200 patients were included in the study, with a mean age of 58.5 ± 11.3 years, of whom 42.0% were male. Obesity (OR=2.83; 95% CI: 1.88-4.26; p<0.001) and hypertriglyceridemia (OR=2.07; 95% CI: 1.17-3.67; p<0.05) were identified as factors significantly increasing the risk of severe osteoarthritis. At 4 weeks and 8 weeks, the Piascledine group showed a reduction in VAS scores from 49.3 ± 19.6mm to 37.6 ± 14.2mm and 25.3 ± 10.2mm, respectively. At 4 weeks, the VAS and WOMAC scores showed greater improvement in the GCS group compared to the Piascledine group. However, at 8 weeks, there was no significant difference in efficacy between the two groups. Treatment with Piascledine slightly increased triglyceride levels from 2.3 ± 1.4mmol/L to 2.7 ± 1.4mmol/L. Side effects were observed in 16.0% of patients during treatment, with the most common being nausea (10.0%).

Conclusion: The study indicates that obesity and hypertriglyceridemia are risk factors for severe knee osteoarthritis. Treatment with Piascledine improves symptoms and knee joint function, without impacting body mass index or lipid metabolism. The majority of side effects were mild and primarily gastrointestinal.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信